NCT01980056 - Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2013

Primary Completion Date

January 19, 2015

Study Completion Date

January 19, 2015

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Vosaroxin

Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle

Trial Locations (1)

10065

Weill Cornell Medical College, New York